Neuraxis Inc. (NRXS) exhibits 84.2% gross margins and -35.0% return on invested capital within Health Care (Biotechnology: Electromedical & Electrotherapeutic Apparatus), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 84.2% gross profitability converts into -60.0% operating margin and -35.0% ROIC, outpacing sector cost of capital.
ROIC: -35.0% // GM: 84.2%YoY revenue trajectory of +32.9% paired with -6.82% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +32.9% // FCF YLD: -6.82%Altman Z-Score of 1.88 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.88 // F-SCORE: 5/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $7.13 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Electromedical & Electrotherapeutic Apparatus require continuous execution to defend -60.0% net margins.
NET MARGIN: -60.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NRXS & activate live FRED threshold breach alerts.